The bill H. B. No. 2025-2026 proposes the enactment of section 3902.65 of the Revised Code, which mandates that health plan issuers apply prescription drug rebates to cost-sharing requirements for covered individuals. The bill defines key terms such as "health plan issuer," "price protection rebate," and "rebate," outlining the conditions under which these rebates must be calculated. Specifically, it requires health plan issuers to determine a covered person's cost-sharing amount at the point of sale based on a price that reflects a 100% reduction of all rebates received or expected in relation to the prescription drug.

Additionally, the bill includes provisions to ensure the confidentiality of rebate information, stating that health plan issuers and their agents cannot disclose the actual amounts of rebates received. It establishes that such information is considered confidential and not public records, thereby protecting the financial and competitive interests of the health plan issuers. Violations of this section are classified as unfair and deceptive insurance acts, subjecting offenders to regulatory proceedings under existing insurance laws.